1. Home
  2. IVT vs ADPT Comparison

IVT vs ADPT Comparison

Compare IVT & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InvenTrust Properties Corp.

IVT

InvenTrust Properties Corp.

HOLD

Current Price

$34.82

Market Cap

2.4B

Sector

Real Estate

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$17.33

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IVT
ADPT
Founded
2005
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.2B
IPO Year
2005
2019

Fundamental Metrics

Financial Performance
Metric
IVT
ADPT
Price
$34.82
$17.33
Analyst Decision
Buy
Strong Buy
Analyst Count
7
9
Target Price
$32.50
$17.78
AVG Volume (30 Days)
658.8K
1.7M
Earning Date
04-28-2026
05-05-2026
Dividend Yield
3.14%
N/A
EPS Growth
647.37
63.89
EPS
0.07
N/A
Revenue
$299,169,000.00
$276,976,000.00
Revenue This Year
$8.42
$3.98
Revenue Next Year
$5.25
$22.72
P/E Ratio
$495.43
N/A
Revenue Growth
9.20
54.77
52 Week Low
$26.52
$9.96
52 Week High
$34.91
$20.76

Technical Indicators

Market Signals
Indicator
IVT
ADPT
Relative Strength Index (RSI) 72.31 66.43
Support Level $30.42 $14.87
Resistance Level N/A $17.52
Average True Range (ATR) 0.71 0.93
MACD 0.21 0.33
Stochastic Oscillator 83.54 81.33

Price Performance

Historical Comparison
IVT
ADPT

About IVT InvenTrust Properties Corp.

InvenTrust Properties Corp is the United States of America based company qualified as a REIT (Real Estate Investment Trust). It is focused on owning, leasing, redeveloping, acquiring and managing a multi-tenant retail platform. The company's wholly-owned and managed retail properties include grocery-anchored community and neighborhood centers and power centers, including those classified as necessity-based. InvenTrust operates through a single segment i.e. multi-tenant retail.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: